...
首页> 外文期刊>Journal of Clinical Microbiology >Laboratory Evaluation of the Liat HIV Quant (IQuum) Whole-Blood and Plasma HIV-1 Viral Load Assays for Point-of-Care Testing in South Africa
【24h】

Laboratory Evaluation of the Liat HIV Quant (IQuum) Whole-Blood and Plasma HIV-1 Viral Load Assays for Point-of-Care Testing in South Africa

机译:在南非进行现场护理的Liat HIV定量(IQuum)全血和血浆HIV-1病毒载量测定的实验室评估

获取原文

摘要

Point-of-care (POC) HIV viral load (VL) testing offers the potential to reduce turnaround times for antiretroviral therapy monitoring, offer near-patient acute HIV diagnosis in adults, extend existing centralized VL services, screen women in labor, and prompt pediatrics to early treatment. The Liat HIV Quant plasma and whole-blood assays, prerelease version, were evaluated in South Africa. The precision, accuracy, linearity, and agreement of the Liat HIV Quant whole-blood and plasma assays were compared to those of reference technologies (Roche CAP CTMv2.0 and Abbott RealTime HIV-1) on an HIV verification plasma panel (n = 42) and HIV clinical specimens (n = 163). HIV Quant plasma assay showed good performance, with a 2.7% similarity coefficient of variation (CV) compared to the Abbott assay and a 1.8% similarity CV compared to the Roche test on the verification panel, and 100% specificity. HIV Quant plasma had substantial agreement (pc [concordance correlation] = 0.96) with Roche on clinical specimens and increased variability (pc = 0.73) in the range of <3.0 log copies/ml range with the HIV Quant whole-blood assay. HIV Quant plasma assay had good linearity (2.0 to 5.0 log copies/ml; R2 = 0.99). Clinical sensitivity at a viral load of 1,000 copies/ml of the HIV Quant plasma and whole-blood assays compared to that of the Roche assay (n = 94) was 100% (confidence interval [CI], 95.3% to 100%). The specificity of HIV Quant plasma was 88.2% (CI, 63.6% to 98.5%), and that for whole blood was 41.2% (CI, 18.4% to 67.1%). No virological failure (downward misclassification) was missed. Liat HIV Quant plasma assay can be interchanged with existing VL technology in South Africa. Liat HIV Quant whole-blood assay would be advantageous for POC early infant diagnosis at birth and adult adherence monitoring and needs to be evaluated further in this clinical context. LIAT cartridges currently require cold storage, but the technology is user-friendly and robust. Clinical cost and implementation modeling is required.
机译:即时护理(POC)HIV病毒载量(VL)测试具有减少抗逆转录病毒疗法监测的周转时间,提供成人附近患者急性HIV诊断,扩展现有集中VL服务,筛查分娩中的妇女并及时提示的潜力儿科要及早治疗。在南非评估了Liat HIV Quant血浆和全血检测(预发行版)。在HIV验证血浆面板()上,将Liat HIV Quant全血和血浆检测的精密度,准确性,线性和一致性与参考技术(Roche CAP CTMv2.0和Abbott RealTime HIV-1)进行了比较。 n = 42)和HIV临床标本( n = 163)。 HIV Quant血浆测定法显示出良好的性能,与Abbott测定法相比具有2.7%的相似度变异系数(CV),与验证板上的Roche试验相比,具有1.8%的相似度CV和100%的特异性。 HIV Quant血浆与罗氏(Roche)在临床标本上具有基本一致性( p c [emcordance相关性] = 0.96),并且变异性( p c > = 0.73),且使用HIV Quant全血检测法在<3.0 log拷贝/ ml范围内。 HIV Quant血浆测定法具有良好的线性(2.0至5.0 log拷贝/ ml; R 2 = 0.99)。与Roche分析( n = 94)相比,在病毒定量为1000拷贝/ ml的HIV Quant血浆和全血分析中,临床敏感性为100%(置信区间[CI], 95.3%至100%)。 HIV Quant血浆的特异性为88.2%(CI,63.6%至98.5%),全血特异性为41.2%(CI,18.4%至67.1%)。没有错过任何病毒学上的失败(向下分类错误)。可以将Liat HIV Quant血浆分析法与南非现有的VL技术互换。 Liat HIV Quant全血测定法将有利于POC出生时的早期婴儿诊断和成人依从性监测,因此需要在此临床背景下进行进一步评估。 LIAT墨盒目前需要冷藏,但是该技术具有用户友好性和鲁棒性。需要临床成本和实施建模。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号